H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...

HC Wainwright issued their Q1 2026 EPS estimates for Outlook Therapeutics in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst D. Tsao anticipates that the company will post ...

H.C. Wainwright initiated coverage of Veritone (VERI) with a Buy rating and $6 price target Veritone designs, develops, and distributes ...

Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 18th. HC ...

H.C. Wainwright adjusted its price target for Largo Resources Ltd. (NASDAQ:LGO) to $3.70, down from the previous $4.20, while maintaining a "Buy" rating on the stock. The firm's decision follows Largo ...

Highlights,Adjusted Q1 2025 EPS projections for Bausch + Lomb as analysts slightly reduce expectations.,Diverse analyst ...

O n Thursday, H.C. Wainwright reaffirmed a positive stance on Altimmune (NASDAQ:ALT) shares, maintaining a Buy rating and a $12.00 price target. Currently trading at $6.99 with a market ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...